Mergers and acquisitions are becoming ever more popular, with activity up 24% in the first two months of this year — after already growing 23% in 2010. Here’s how your portfolio can benefit from this trend.
Co…
The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimate…
“Do not not divide, crush, chew, or dissolve the tablet,” reads the label on packages of Johnson & Johnson’s Sudafed allergy and cold medicine. The company is recalling 667,632 packages for the typographical error.
…
Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting — if not always positive — year. Here’s our rundown of the…
On Wednesday, a Minneapolis jury ordered Johnson & Johnson subsidiary Ortho-McNeil-Janssen Pharmaceuticals to pay an 87-year-old man $1.7 million because its antibiotic Levaquin damaged his Achilles tendons. It was the first ve…